Introduction {#Sec1}
============

Carcinosarcoma or malignant mixed Mullerian tumors (MMMT) are biphasic tumors that contain malignant mesodermal and epithelial components, in contrast to sarcomas, which contain exclusively malignant mesodermal elements (Kernochan and Garcia [@CR16]). Typically, the metastatic sites mainly consist of carcinoma elements (Silverberg et al. [@CR32]). Due to their rareness, there are no large epidemiological studies available and data are in general inconclusive. It has been proposed that the epithelial and sarcomatous elements develop from the same stem cell, with the carcinoma component being undifferentiated and of a specific histotype, whilst the sarcomatous component shows a mixed homologous appearance (McCluggage [@CR25]; Gorai et al. [@CR11]). Relapse-free and overall survival in MMMT-E is poor, and treatment failure at the time of recurrence appears to be at distant sites (Gadducci et al. [@CR8]; Gonzalez Bosquet et al. [@CR10]; Yamada et al. [@CR40]; Manolitsas et al. [@CR24]; Vorgias and Fotiou [@CR38]). Surgical therapy is the initial treatment modality and necessitates hysterectomy, bilateral salpingo-oophorectomy and at least pelvic lymphadenectomy (NCCN [@CR28]). If metastatic disease is present, there is a need for full cytoreduction, which can be achieved in 57% of patients, resulting in a significant improvement of median overall survival (OS 53.3 vs. 8.6 months) (Tanner et al. [@CR35]).

The benefit of chemotherapy for MMMT-E has been clearly shown, with active substances being cisplatin, carboplatin, ifosfamide, anthracyclines and paclitaxel (Sutton et al. [@CR33], [@CR34]). It has been proposed that FIGO Stage I patients should be treated with 4 cycles and Stage II--IV patients with 6 cycles of carboplatin and epirubicin (Manolitsas et al. [@CR24]; Berton-Rigaud et al. [@CR2]; Wolfson et al. [@CR39]). A recent Cochrane review including 579 patients from two randomized studies compared adjuvant radiotherapy with combination chemotherapy (ifosfamide with paclitaxel versus ifosfamide alone) in recurrent Stage III/IV MMMT-E, finding an improved OS in the combination chemotherapy treatment arms (Sutton et al. [@CR33]; Homesley et al. [@CR13]; Galaal et al. [@CR9]). The promising survival data from various studies and the reduced toxicity found in the carboplatin and paclitaxel combination treatments which are predominantly used in endometrial and ovarian adenocarcinoma, led several institutions, including our own, to change the chemotherapy regimen in MMMT-E to this more tolerable combination. However, there is no established consensus for therapeutic management in this patient group (Berton-Rigaud et al. [@CR2]; NCCN [@CR28]). With only a few prospective randomized controlled trials reported in MMMT-E, the optimal chemotherapy modality is yet to be determined, particularly in view of new targeted therapies.

Therefore, this study retrospectively analyzed the outcomes of a large cohort of MMMT-E to evaluate the response to various kind of adjuvant chemotherapies.

Materials and methods {#Sec2}
=====================

Cohort description and outcome analysis {#Sec3}
---------------------------------------

We reviewed all patients with MMMT-E treated with an adjuvant platinum-based chemotherapy in the Gynecological Cancer Centre of the Royal Hospital for Women in Sydney, Australia and the Gynecological Cancer Centers of the University Hospitals Zurich and Basel, Switzerland between 1988 and 2014 (*N* = 103). For each case, at least 1 control of EC (*N* = 172) and OC (*N* = 189) undergoing adjuvant platinum-based therapy was matched by age and FIGO Stage from the equivalent databases available. Data of cases and controls were obtained using paper and electronic patient records, as available, and the following parameters were collected and stored in an in-house study database: histological diagnosis and histotype of tumor, depth of myometrial invasion and involvement adjacent tissues, lymphvascular space invasion, age, BMI, menopausal status, menstrual status, HRT, type and duration of symptoms, date of diagnosis (matched), Stage of disease (FIGO I/II and III/IV, matched), grade, surgical procedure and its duration, blood loss and complications, lymphadenectomy including number of nodes removed, residual disease after primary surgery, chemotherapy regimen, number of cycles, response to treatment, time to progression, radiation treatment and date of death/relapse or last follow-up. Time to progression was defined as the time between the first day of treatment and either radiologic evidence of progressive disease or the first day of second-line treatment, whichever came first. Follow-up for all patients after treatment was at least every 3 months for the first 2 years, at least every 6 months for the subsequent 3 years and thereafter yearly for another 5 years or until death.

Next-generation sequencing and immunohistochemistry {#Sec4}
---------------------------------------------------

Due to the results retrieved from this retrospective analysis in MMMT-E, it was decided to continue along the lines also for MMMT-O. For this purpose, a prospective US-American cohort of 450 MMMT-O and 1290 high-grade serous ovarian cancers (HGSOC) which underwent immunohistochemistry (IHC) and next-generation sequencing (NGS) within a commercially CLIA-certified molecular profiling laboratory as referrals from 2008 to 2016 was used (Caris Life Sciences, Phoenix, AZ, USA). The tissue diagnoses were submitted based on pathological assessment of physicians who requested the assays and were further verified by a pathologist at the Caris Laboratory. IHC was performed on formalin-fixed paraffin-embedded tumor samples using commercially available detection kits, automated staining techniques (Benchmark XT, Ventana, Tucson, AZ, USA), antibodies against ERCC1 (Clone 8F1, Abcam), TUBB3 (Clone PRB-435P, BioLegend) and TOP2A (Clone 3F6, Leica Biosystems). ERCC1 loss was defined as ≤ 2 + staining in less than 50% of tumor cells or 3 + staining in less than 10% of tumor cells. TUBB3 loss was defined as less than 2 + staining present in less than 30% of tumor cells. A positive result for TOP2A was reported if at least 1 + staining was observed in 10% or more of tumor cells. Test results from the company's commercial biomarker database were obtained anonymously using a data extraction tool.

Statistical analyses {#Sec5}
--------------------

Descriptive statistics for study groups were presented using mean ± standard deviation (SD) or counts and percentages as appropriate. *P* values were calculated using T-tests or Fisher's exact tests. Time to event was analyzed using Cox regression with corresponding hazard ratios (HR), 95% confidence intervals (CI), *P* values and the Kaplan--Meier method. A *P* value \< 0.05 is considered as significant. Evaluations were done using the statistical software R version 3.1.1. Biomarker expression was compared across histologic subtypes via unpaired *t* tests using GraphPad software (GraphPad Software Inc, La Jolla, CA, USA).

Results {#Sec6}
=======

We analyzed 103 histologically confirmed MMMT-E cases against 378 controls, consisting of 172 EC, 189 OC and 17 MMMT-O. The clinicopathological characteristics showed statistically significant differences for death from disease, age, BMI, FIGO Stage, grade, histotype, type of chemotherapy, adjuvant radiotherapy, residual disease, and lymph node dissection (*P *≤ 0.001, Table [1](#Tab1){ref-type="table"}). Approximately, one-third of patients with MMMT-E (31.1%) and MMMT-O (35.5%) died due to their disease by the end of this study, in contrast to one tenth (9.9%) of EC and one-fifth (19%) of OC patients. Almost two-thirds (64.9%) in the MMMT-E study group and three quarters (76.4%) of the EC cases were early FIGO Stage I/II patients, in contrast MMMT-O (17.6%) and OC (32.4%). MMMT-O and OC patients were mainly advanced FIGO Stage III/IV cases (82.4% and 67.6%, respectively). Significantly more undifferentiated and high-grade cancers were found in MMMT-E and MMMT-O patients (82.2 and 93.3%, respectively) than in EC and OC patients (33.5% and 66.5%, respectively). Mainly, mixed and endometrioid histotypes were found in the MMMT-E study group ("other", 71.4%) and in MMMT-O (55.6%) and EC (83.11%) patients; whereas OC patients were predominately of serous (66.7%). A total of 222 patients received adjuvant chemotherapy, hereby platinum and either different anthracyclines or ifosfamide were mainly given in MMMT-E (88.7%) and less in EC (31.6%), MMMT-O (42.7%) and OC (14.7%). In contrast, a platinum/taxane regimen was used most commonly in OC (85.3%), MMMT-O (57.1%), EC (68.7%) and only in 11.3% in MMMT-E. Adjuvant radiotherapy was applied in 65.3% to MMMT-E, 45.9% to EC, and 26.7% to OC.Table 1Clinicopathological characteristics of the Swiss/Australian cohortMMMT-E *N*=103\
21.4%EC\
*N*=172\
35.8%MMMT-O *N*=17\
3.5%OC\
*N*=189\
39.3%Overall\
*P* value*N*\
481Age (years) Mean ± SD68.8±11.266.6±11.868.2±12.063.3±12.90.001481BMI Mean ± SD28.9±7.833.5±10.526.5±6.726.6±6.0\< 0.001274FIGO stage9416517185\< 0.001461 Stage I/II61 (64.9%)126 (76.4%)3 (17.6%)60 (32.4%)250 Stage III/IV33 (35.1%)39 (23.6%)14 (82.4)125 (67.6%)211Grade4516415161385 Grade 337 (82.2%)55 (33.5%)14 (93.3%)107 (66.5%)\< 0.001213 Other8 (17.8%)109 (66.5%)1 (6.7%)54 (33.5%)172Histotype351729188\<0.001404 Serous10 (28.6%)29 (16.9%)4 (44.4%)126 (67.0%)169 Other25 (71.4%)143 (83.1%)5 (55.6%)62 (33.0%)235Chemotherapy531914136\< 0.001222 P/A47 (88.7%)6 (31.6%)6 (42.9%)20 (14.7%)79 P/T6 (11.3%)13 (68.4%)8 (57.1%)116 (85.3%)143Adjuvant RT95981715\< 0.001222 Yes62 (65.3%)45 (45.9%)0 (0%)4 (26.7%)111RD7162169\< 0.001158 None59 (83.1%)53 (85.5%)7 (43.8%)6 (66.7%)122LND9574158\< 0.001192 Any66 (69.5%)43 (58.1%)2 (13.3%)5 (62.5%)116 n.d.29 (30.5%)31 (41.9%)13 (86.7%)3 (37.5%)76DOD32 (31.1%)17 (9.9%)6 (35.3%)36 (19.0%)\< 0.00191*EC* endometrial cancer, *MMMT-E* malignant mixed Mullerian tumors of the endometrium, *MMMT-O* malignant mixed Mullerian tumors of the ovary, *OC* ovarian cancer, *BMI* body mass index, *P/A* platinum/anthracycline, *P/T* platinum/taxol, *RT* radiotherapy, *RD* residual disease, *LND* lymph node dissection done ("any") or not done ("n.d."), *DOD* death of disease; statistical significance given by *P* values

We compared the long-term outcome, expressed as the cumulative risk of relapse, over a period of 20 years regardless of FIGO Stage. The cumulative relapse risk initially increased for all four cancers, strongest for MMMT-O patients and to comparable extents for OC, EC, and MMMT-E (Fig. [1](#Fig1){ref-type="fig"}). Intriguingly, however, the cumulative risk for MMMT-E patients remained stable, namely reaching a plateau after 2.5 years until the end of the observation period (20 years); whereas, it further increased for the three other cancers to differing extent over this time period. We speculated as to whether the observed divergent survival results for MMMT-E and EC was dependent on the FIGO Stage. The relapse-free survival of MMMT-E and EC were, therefore, compared for early Stage (FIGO I/II) (Fig. [2](#Fig2){ref-type="fig"}a) and late Stage (FIGO III/IV) (Fig. [2](#Fig2){ref-type="fig"}b) patients in a Kaplan--Meier presentation. Indeed, the relapse-free survival rate of early Stage MMMT-E patients decreased to a greater extent within the first 2.5 years when compared to EC patients, but then remained stable at 0.75, meaning that 75% of MMMT-E patients remained without any case of recurrence occurring for 20 years. The relapse-free survival rate of early FIGO stage EC patients was significantly different from that of the MMMT-E patients (strong intersection of the curves, test for proportional hazard *P *\< 0.001) and decreased to a lesser extent than in MMMT-E patients within the first 2.5 years but then further decreased within the subsequent 11.5 years. The respective relapse-free survival rates for advanced FIGO Stage MMMT-E and EC patients decreased to a comparable extent (proportional hazard *P *= 0.118).Fig. 1Cumulative 20-year risk for relapse in MMMT-E, EC, MMMT-O and OC in our cohort. After an initial increase within 2.5 years, the cumulative hazard for relapse remained constant for MMMT-E (red line), whereas it continuously increased for endometrial cancer (black line), ovarian cancer (blue), and MMMT-O (green) over the yearsFig. 2Kaplan--Meier curve comparing early Stage (FIGO I/II) and late Stage (FIGO III/IV) MMMT-E and EC patients. Relapse-free survival for **a** early Stage MMMT-E patients (red line) reached plateau at 2.5 years and remains constant until the end of the observation period (20 years), whereas it further decreased for the respective EC patients with time (observation period 14 years); and **b** late Stage MMMT-E reached a plateau after 2.75 years, meaning that almost a quarter of these patients did not relapse after this time until the end of the observation period (5 years), whereas all EC patients relapsed already after 2.25 years. Hence, the early FIGO Stage I/II MMMT-E patients account for the observed plateau after 2.5 years

We also analyzed whether the choice of the chemotherapy regimen affected the observed favorable relapse-free survival of MMMT-E patients, regardless of FIGO Stage. Indeed, a significantly shorter time to relapse for patients receiving platinum and taxanes than those receiving platinum and anthracyclines or ifosfamide was observed (HR 4.69, CI 1.23--17.87, *P *= 0.024, Fig. [3](#Fig3){ref-type="fig"}). This indicates that MMMT-E patients who received taxane-free platinum combination chemotherapy and particularly Stage FIGO I/II MMMT-E patients who do not relapse within the first 2.5 years have excellent long-term survival outcomes.Fig. 3Kaplan-Meier curve comparing relapse-free survival in MMMT-E patients subjected to platinum chemotherapy with or without taxanes. MMMT-E patients receiving platinum and taxanes (Plat/Tax: red line) had a substantially worse relapse-free survival and shorter time to relapse (median: 1.29 years) than those with platinum and anthracyclines or ifosfamide (Plat/noTax: black line. Median time to relapse not available as median not reached) (HR 4.69, CI 1.23--17.87, *P *= 0.024)

The increased risk of relapse in MMMT-E patients receiving taxane-based chemotherapy prompted us to also examine whether a similar effect could be present in MMMT-O. We, therefore, examined the mutational load and the protein expression of various drug targets in a large independent US-American cohort of MMMT-O (*N *= 450). MMMT-O and HGSOC (*N* = 1290) displayed a similarly high load of *p53* mutations (77.8% vs 80.2%, Fig. [4](#Fig4){ref-type="fig"}a). In contrast, significant differences were found for *KRAS* and *PI3KCA* mutations, both being more frequent in MMMT-O compared to HGSOC (*KRAS:* 5.7% vs 2.4%, *P *= 0.015; *PI3KCA:* 6.2% vs 3.3%, *P *= 0.018).Fig. 4Mutational load in MMMT-O and HGSOC and expression of chemotherapy target proteins in MMMT-O. **a** NGS-data showing the mutational load (frequency expressed in %, *y*-axis) in MMMT-O (green) and HGSOC (blue). Mutation frequency expressed as percentage (*y*-axis) is plotted against selected gene mutations (*x*-axis). *KRAS* and *PIK3CA* mutations were significantly more frequent in MMMT-O than in HGSOC (*P *= 0.015 and *P *= 0.018, respectively). **b** Presumed chemosensitivity (expressed as percentage, *y*-axis) for MMMT-O based on the predictive biomarker expression for the combination of platinum with taxanes (left), with anthracyclines (middle), and with alkylating agents (right). Results of the prediction of sensitivity were based on whether none (red), one (orange) or both (green) of the biomarkers were expressed. Highest presumed sensitivity in MMMT-O was for the carboplatin/anthracycline combination (73.9%; green, middle)

The majority of proteins selected showed a statistically significant difference in the expression between MMMT-O and HGSOC (Supplement Table S1). These results, therefore, suggest that crizotinib (targeting ALK), cetuximab (EGFR), topotecan (TOPO1), anthracyclines (TOP2A), and alkylating agents such as ifosfamide (MGMT loss) would have a potential treatment benefit in MMMT-O. We next calculated a presumed sensitivity for the chemotherapy combination carboplatin/taxane compared to carboplatin/anthracycline or carboplatin/alkylating agents in MMMT-O. Hereby, the prediction of sensitivity to platinum/taxane combination was based on the loss of expression of ERCC1 and TUBB3 proteins, the prediction for the platinum/anthracycline combination was based on ERCC1 loss and TOP2A expression, and the prediction of platinum/alkylating agents combination was based on ERCC1 loss and MGMT loss. The results demonstrated for MMMT-O a presumed chemotherapy sensitivity of 39.5% for a combination of carboplatin/taxane, of 73.9% to a combination of carboplatin/anthracyclines, and of 24.2% to a combination of carboplatin alkylating agents (Fig. [4](#Fig4){ref-type="fig"}b). These data suggest that not only MMMT-E but also MMMT-O patients may benefit from a taxane-free chemotherapy.

Discussion {#Sec7}
==========

It is increasingly important to define malignant diseases in relation to their genomic similarity instead of the organ of origin. This has been nicely shown in the M-PACT-trial from the US-National Cancer Institute, where the intention was to detect the molecular signature of diseases, rather than classify them by the tissue of origin. Subsequently, patient outcomes were examined according to mutations for *p53* and *PIK3CA*. Whilst the curves initially looked genetically driven, they diverged when the researchers looked at the tissue of origin (Schott et al. [@CR30]).

MMMT of endometrial and ovarian origin share the same histological signature but their genetic similarity is still widely unknown. As MMMT-E and MMMT-O derive from different organs, they are not managed identical but due to the tissue of origin. One study suggests that MMMT-O and MMMT-E are different diseases in terms of their genetic landscape. In this study, 110 MMMT-O, 141 MMMT-E and 1587 OC of all histotypes where compared. *TP53* was the most commonly mutated gene in all three cancers with 76.4% in MMMT-O, 68.8% in MMMT-E and 69% in OC. Genetic alterations of *PI3K/AKT/mTOR* and *MAPK* pathways were noted to be similar in MMMT-O and OC but less frequent in MMMT-E (*p *\< 0.001). In OC, the chance of having a BRCA1/2 mutation was highest compared to MMMT-E and MMMT-O (20% and 18% vs. 9%, respectively) (Mahdi et al. [@CR22]). These data are similar to our own NGS analysis; however, we have 4-times more numbers of MMMT-O included and compared them to the most aggressive subtype of OC, HGSOC. Our own data in conclusion with the literature demonstrate a higher rate of *KRAS* and *PI3KCA* mutations in MMMT-O compared to HGSOC.

Since MMMT are known to be metaplastic carcinoma, they are no longer considered a subtype of sarcoma or managed as such. Instead, despite the lack of specific data, the management of MMMT has been extrapolated from studies of EC and OC (Berton-Rigaud et al. [@CR2]; Cantrell et al. [@CR4]). In the past 13 years, 9 GOG trials were performed in MMMT-E and MMMT-O. In total, 21 studies were found in our systematic literature search. Hereby, 16/21 were performed in MMMT-E only, 4/21 in MMMT-O only and 1/21 in both types (Table [2](#Tab2){ref-type="table"}). In total, 1214 patients were included in these heterogeneous studies. The largest GOG trial incorporated 206 patients, but most studies examined MMMT numbers below 100, which clearly limits its results. Cisplatin-based chemotherapy and adjuvant setup were most commonly studied (67%), hereby the drug combination was mainly platinum plus paclitaxel or ifosfamide. Throughout these investigations, with mostly insufficient numbers of MMMT-E and MMMT-O patients, best response rate of a combination of carboplatin and paclitaxel was 62% and 55%, respectively, and 5-year overall survival 62--88% and 30%, respectively (Table [2](#Tab2){ref-type="table"}). These data differ from our own results and might be due to the heterogeneity of the various cohorts and the small patient numbers in the published literature.Table 2Published studies on treatment modalities for MMMT-E and MMMT-OAuthorsJournal (year)*N*DesignDiseaseTreatmentOutcomeFowler, GOG Study GroupGynecol Oncol ([@CR7])28ProspectiveMMMT-EStage III/IV persistent or recurrentTrimetrexate 5 mg/m^2^ b.i.d. for 5 days and repeated in 14 daysOverall RR 4.8%.DuskaGynecol Oncol ([@CR5])55RetrospectiveMMMT-OStage II--IVCarboplatin/PaclitaxelComplete CR 55%; OS 27.1 monthsThipgen, GOG Study GroupGynecol Oncol ([@CR500])136ProspectiveMMMT-OCisplatin (50 mg/m^2^) every 3 weeks until progression or toxicityRR 20%, similar to MMMT-ESutton, GOG Study GroupGynecol Oncol ([@CR34])76ProspectiveMMMT-EStage I/IIIfosfamide 1.5 g/m^2^ iv); Cisplatin 20 mg/m^2^5-year OS 62%Miller, GOG Study GroupGynecol Oncol ([@CR26])51ProspectiveMMMT-EPersistent or recurrentPhase II Topotecan 1.5 mg/m^2^ iv until progression or toxicityNo major activityHomesley, GOG Study GroupJCO ([@CR12])179ProspectiveMMMT-EStage III/IV persistent or recurrentPhase III Ifosfamide 2.0 g/m^2^ iv or Ifosfamide 1.6 g/m^2^ iv and Paclitaxel 135 mg/m^2^Median PFS and OS, combination treatment 3.6 v 5.8 v 3.6 and 13.5 v 8.4 monthsLeiserGynecol Oncol ([@CR18])30RetrospectiveMMMT-OStage II--IVPlatinum and Taxane5-year OS 30%Wolfson, GOG Study GroupGynecol Oncol ([@CR39])206ProspectiveMMMT-EStage I--IVWAI or 3 cycles of Cisplatin and IfosfamideChemotherapy arm lower RR 21% and death rate 29%MakkerGynecol Oncol ([@CR23])49RetrospectiveMMMT-EStage I--IVPaclitaxel--Carboplatin; Ifosfamide--Platinum; other CT; RT concurrent or alonePaclitaxel--Carboplatin most efficaciousSignorelliInt J Gynecol Cancer ([@CR31])41RetrospectiveMMMT-OCisplatin, Adriamycin, and Cyclophosphamide vs Cisplatin, Epirubicin, and IfosfamideCisplatin, Adriamycin, and Cyclophosphamide:good RR but high toxicityHoskinsGynecol Oncol ([@CR14])39ProspectiveMMMT-EPaclitaxel 175 mg/m^2^, carboplatin (AUC 5-6) for 3-6 cycles ± radiationRR 55--60%Miller, GOG Study GroupGynecol Oncol ([@CR27])28ProspectiveMMMT-EPersistent or recurrentPhase II gemcitabine 600 mg/m^2^ and Docetaxel 35 mg/m^2^ iv days 1, 8 and 15 until progression or toxicityDocetaxel and Gemcitabine not activeGalaalCochrane Database Syst Rev ([@CR9])579RetrospectiveMMMT-EPersistent or recurrentRT and/or systemic chemotherapyChemotherapy with Ifosfamide and Paclitaxel should be consideredLacourInt J Gynecol Cander ([@CR17])23ProspectiveMMMT-EPersistent or recurrentPhase II single arm 6 cycles of Carboplatin/Paclitaxel 3wRR 62 %EinsteinGynecol Oncol ([@CR6])27ProspectiveMMMT-EIfosfamide (1.2 g/m^2^ and Cisplatin (20 mg/m^2^ vs Ifosfamide alone 3 cycles followed by pelvic external beam RT and brachytherapy followed by 3 additional cyclesNo significant activityAghajanian, GOG Study GroupGynecol Oncol ([@CR1])17ProspectiveMMMT-EPaclitaxel 175 mg/m^2^ iv, Carboplatin AUC 6, Iniparib 4 mg/kg iv until disease progression or toxicityNo significant activityCampos, GOG Study GroupGynecol Oncol ([@CR3])22ProspectiveMMMT-ERecurrencePhase II, second-line Pazopanib orally 800mgMinimal activityLorussoInt J Gynecol Cancer ([@CR20])46RetrospectiveMMMT-EStage I--IVCisplatin 20 mg/m^2^ and Ifosfamide 1500 mg/m^2^ vs Carboplatin AUC 5 and Paclitaxel 175 mg/m^2^Same efficiency but better toxicity profile with Carboplatin-PaclitaxelOtsukiInt J Gynecol Cancer ([@CR29])51ProspectiveMMMT-EComplete resectionPhase II single arm: 6 courses of 175 mg/m^2^ Paclitaxel and Carboplatin AUC 6Combination of Paclitaxel and Carboplatin feasible and effective, 78.2% PFS, 87.9% OSVandenputInt J Gynecol Cancer ([@CR37])69RetrospectiveMMMT-E and ECStage I--I complete StagingPlatinum-based CT or no adjuvant therapyRFS better with Platinum-based CT 22 vs. 10 monthsMackayGynecol Oncol ([@CR21])41ProspectiveMMMT-E MMMT-OSarcoma Metastatic diseasePhase IIVEGF TRAP (Aflibercept) Single Agent trialMinimal activity*GOG* Gynecologic Oncology Study Group, *RR* response rate, *OS* overall survival, *PFS* progression-free survival, *WAI* whole-abdominal irradiation, *CT* chemotherapy, *TR* radiation therapy, *AUC* area under the curve

Targeted drug trials have been scarce for MMMT with only two studies examining the role of VEGF-directed therapy, one with pazopanib (MMMT-E), the other with aflibercept (MMMT-E and MMMT-O), both demonstrating only a minimal efficacy (Campos et al. [@CR3]; Mackay et al. [@CR21]). Our large retrospective case--control study with over 20 years of follow-up has clearly shown that the combination of carboplatin/taxanes is less efficient in MMMT-E. Our exploratory data further suggest that the same could be the case for MMMT-O.

The concept of personalized treatment is based upon NGS, CISH and IHC data on potentially targetable biomarkers that describe an individual molecular footprint of a tumor (Janssens et al. [@CR15]). Using precision IHC, we found proteins that were differentially expressed between MMMT-E and MMMT-O. It has been hypothesized that these markers could be associated with the likelihood of response to chemotherapy. If confirmed, this may explain the poorer performance of the current standard treatments. Obviously, this is only a hypothesis generating observation and a carefully designed prospective clinical trial would be necessary to validate these findings.

The rarity of MMMT, in particular of MMMT-O, accounts for the fact that subgroup analyses in randomized controlled chemotherapy trials can rarely be performed because of a lack of statistical power. Secondly, different histopathological definitions of MMMT make it difficult to compare studies that focus on this group. Thirdly, many reports combine MMMT-E and MMMT-O with their organ-based adenocarcinoma counterparts. Treatment options tailored to the mutational driver *p53* or *KRAS/PI3KCA* as shown in our NGS analysis should, therefore, be considered in future studies to tailor treatment in relation to the genetic origin. For this, collaborative studies within trial networks performing whole genomic sequencing of these tumors is needed to identify potential targeted therapies for the future.

Electronic supplementary material
=================================

 {#Sec8}

Below is the link to the electronic supplementary material. Supplementary material 1 (DOCX 24 kb)

**Publisher\'s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Viola Heinzelmann-Schwarz and André B. Kind contributed equally.

We acknowledge the pathologists, medical and gynecological oncologists who were involved in the diagnosis and care of the examined patients at the Royal Hospital for Women, Sydney, the University Hospital Zurich and the University Hospital for Women, Basel.

This work was supported by the Cancer Institute NSW (09/CRF/2-02 to VHS.); RANZCOG (to VHS); William Maxwell Trust (to VHS); Swiss National Foundation (310030-156982 to VHS) and Oncosuisse (KFS_3013_08_2012 to VHS).

All authors declare that they have no conflict of interest.

The study was approved by the various institutional review boards (SPUK, Canton of Zurich, Switzerland, Hunter Area Research Ethics 04/04/07/3.04; South Eastern Sydney Illawarra HREC/AURED Ref: 08/09/17/3.02, 08/09/17/3.02; StV06/2006).
